A previously published article presented difficulties with the revised European guidelines on sterile manufacturing. The authors included a brief summary of the comments developed on the draft document. This article expands upon that summary, outlines the authors' rationale, and highlights the most difficult aspects of the revision draft.
Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.
The European Medicines Agency has called for the immediate suspension and recall of AbbVie and Biogen's multiple sclerosis drug Zinbryta (daclizumab beta).
The FDA commissioner outlined the agency's initiatives to reward innovation and biosimilars development.
With minimal damage to its manufacturing plant in Humacao, Puerto Rico, Colorcon has been able to restore full operations.
The agency has approved a new HIV treatment for patients with "limited treatment options".
This article presents considerations for preventing hazards associated with dust in pharmaceutical production, particularly as relates to the United Kingdom's Control of Substances Hazardous to Health (COSHH) Regulations.
Twenty-first century drug development challenges sponsors and contract partners to collaborate more closely, using tools such as model-based simulation.
The company is recalling Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g manufactured by Gland Pharma Ltd and distributed by Sagent due to out-of-specification impurity results.
The company is recalling three lots of Hydromorphone HCl Injection USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials because of possibly empty or cracked vials.
The upcoming serialization deadline and the United Kingdom's departure from the European Union could result in supply bottlenecks.
This article describes a new, combined, quantitative method for assessing excipient risks that has been developed by the authors as one possible risk evaluation method.
Manufacturers face demands for timely information on clinical studies, product recalls, and approvals.
In-house experts can help select the right systems and suppliers, making validation and compliance easy, says Siegfried Schmitt, principal consultant at PAREXEL.
FDA enforcement efforts and drug approvals trend upward.
Drug companies must consider all factors impacting the cost of drugs, including high costs of early development stages.
Robert Iser of PAREXEL Consulting answers questions regarding the regulatory expectations of quality agreements and how companies can ensure the quality and safety of their products.
Stability testing on APIs/finished drug product helps define optimal drug packaging for shelf-life storage.
Tableting instruments (i.e., compaction simulators) that simulate high-speed presses can be used in a quality-by-design (QbD) approach to perform in-depth material characterization and direct scale-up.
GlaxoSmithKline has issued a voluntary recall of three lots of respiratory inhalers in the United Kingdom, including preventer and emergency relief inhalers.
Materials used in the seals of split butterfly valves for aseptic pharmaceutical manufacturing should be chosen carefully.
The agency clarifies recommendations found in ICH Q11 about chemical entities and biotechnology entities.
The company is voluntarily recalling three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial and one lot of Labetalol Hydrochloride Injection, USP, Novaplus because of the potential of cracked glass at the rim of the vials.
An architect's evaluation early in a pharmaceutical facility relocation and design process can help identify potential problems.
The agency released draft guidance on the format for electronic submissions of NDA and BLA content regarding the planning of bioresearch monitoring inspections.
